Table 2:

Characteristics of and weight reduction efficacy in experimental studies analyzing anti-obesity medications in older adults

Reference	Study Name	Secondary analysis	Total sample size	Sample aged ≥65	% of population ≥65	Intervention medication and dose(s)	Comparison group	Duration	Weight change in intervention group	Weight change in comparison group	Estimated treatment difference
Manuscripts
Varli et al. 2010		No	13	13	100.0%	Orlistat 120 mg tid	N/A	24 weeks	−8.4% (SD=1.2 kg)	N/A	−8.4% (SD=1.2 kg)
Gadde et al. 2011	CONQUER	Yes	2487	219	8.8%	Phentermine 7.5 mg – topiramate 46 mg Phentermine 15 mg – topiramate 92 mg	placebo	56 weeks	−7.8% (5.7%–9.9%) −9.4% (8.0%–10.9%)	−3.2% (1.6%–4.7%)	−4.6% −6.2%
Ryan et al. 2024	Weight-reduction outcome in SELECT	Yes	17604	6728	38.2%	Semaglutide 2.4 mg	Placebo	59 months	NA	NA	Age 65 to <75 −8.1% (−8.53 to −7.66) Age ≥75 −7.49% (−8.37 to −6.62)
Abstracts
Wilding et al. 2018	SCALE Obesity and Pre-diabetes	Yes	3652	201	5.5%	Liraglutide 3.0 mg	placebo	56 weeks	–8.4%	–4.2%	−4.2%
Wilding et al. 2018	SCALE diabetes	Yes	621	119	19.2%	Liraglutide 3.0 mg	placebo	56 weeks	–7.2%	–2.5%	−4.7%
Kushner et al. 2022	Body Composition sub-study in SURMOUNT-1	Yes	255	20	7.8%	Tirzepatide 5 mg, 10 mg, 15 mg	Placebo	72 weeks	–22%	–3.8%	–18.2%